Immunic, Inc. Common Stock IMUX
Analyst Ratings
- Consensus
- Buy — 6 Buy · 1 Hold · 0 Sell (7 analysts)
- Avg. Price Target
- $37.80 (+367.8% upside)
Key Stats
- Today's Range
- $7.99 – $8.22
- 50-Day Range
- $6.35 – $17.18
- 52-Week Range
- $5.06 – $17.43
- Volume
- 38K shs
- Average Volume
- 423K shs
- Market Cap
- $108.88 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 2.84%
- Days to Cover
- 1.00
About Immunic, Inc. Common Stock
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Related Stocks
Compare head-to-head: IMUX vs LLY·IMUX vs JNJ·IMUX vs ABBV·IMUX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.